Evidence map›Paper›PMID 41246462›Full record

ArticleIJTLD open2025

Diagnostic accuracy of the Cepheid MTB host response assay for the detection of pulmonary TB.

Y Alkabab, Y Rani, M Farhad, C Zamudio, T Caceres, H Cox, W Dowling, E Nakabugo, L Nakiyingi, C Hoang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Y AlkababMedical University of South Carolina, Charleston, SC, USA.
Y RaniFrontier Science Foundation, Brookline, MA, USA.
M FarhadFrontier Science Foundation, Brookline, MA, USA.
C ZamudioUniversidad Peruana Cayetano Heredia, Lima, Peru.
T CaceresUniversidad Peruana Cayetano Heredia, Lima, Peru.
H CoxUniversity of Cape Town, Cape Town, South Africa.
W DowlingUniversity of Cape Town, Cape Town, South Africa.
E NakabugoMakerere University, Kampala, Uganda.
L NakiyingiMakerere University, Kampala, Uganda.
C HoangNational Lung Hospital, Hanoi, Vietnam.
N Van HungNational Lung Hospital, Hanoi, Vietnam.
H LipsonRutgers New Jersey Medical School, Newark, NJ, USA.
H JinnaRutgers New Jersey Medical School, Newark, NJ, USA.
D T ArmstrongJohns Hopkins University, Baltimore, MD, USA.
A BorkmanMedical University of South Carolina, Charleston, SC, USA.
M de VosFoundation for Innovative New Diagnostics, Geneva, Switzerland.
S KimFrontier Science Foundation, Brookline, MA, USA.
S E DormanMedical University of South Carolina, Charleston, SC, USA.
A P NicholsonFoundation for Innovative New Diagnostics, Geneva, Switzerland.
FEND-TB Consortium

Funding

FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
NIAID NIH HHS U01 AI152084
6 · The paper itself

Abstract

backgroundCurrent sputum-based diagnostic approaches fail to identify some individuals with active TB, underscoring the need for tests that do not rely on sputum. This study assessed the diagnostic accuracy of the Xpert MTB Host Response (Xpert HR) blood test for detecting pulmonary TB.

methodsWe conducted a prospective study in adults with pulmonary TB symptoms who underwent Xpert HR testing. Diagnostic accuracy was assessed against a microbiological reference standard of sputum cultures and molecular testing.

resultsAmong 813 participants, 52% were female, median age was 38 years, and 192 (24%) were HIV-positive. For Xpert HR performed using capillary blood, sensitivity was 91% (95% confidence interval [CI]: 86-94), specificity was 45% (95% CI: 41-49), and area under the receiver operating characteristic curve was 0.85 (95% CI: 0.81-0.89). Country-specific differences in performance were observed. Sensitivity was 93% (95% CI: 76-98) and specificity was 18% (95% CI: 13-27) among people living with HIV.

conclusionThe Xpert HR TB assay demonstrated promising sensitivity, but its specificity did not meet minimum target product profiles for a TB triage or case detection test. In its current form, Xpert HR cannot replace more sensitive nucleic acid amplification tests in sputum-productive individuals.

Indexed as

diagnostic accuracyhost responseMycobacterium tuberculosissensitivityspecificitytuberculosis

Identifiers

PMID41246462
PMCPMC12617089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.